Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review

SIMPLE SUMMARY: In this article, we outline updates on the clinical development of savolitinib, a novel, reversible c-MET kinase inhibitor conditionally approved in China for treatment of advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping mutation (METex14). Savoliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaokuan, Lu, Yao, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776447/
https://www.ncbi.nlm.nih.gov/pubmed/36551608
http://dx.doi.org/10.3390/cancers14246122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776447/
https://www.ncbi.nlm.nih.gov/pubmed/36551608
http://dx.doi.org/10.3390/cancers14246122

Ejemplares similares